Japan Approves First Humira Biosimilar

Mylan Will Market Fujifilm Kyowa Kirin’s Adalimumab Rival In Japan

 
• By Dave Wallace

Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.

Thumbs_Up_Japan
Japan has given the nod to its first adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products